Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$1.73B |
| 2 |
ONC
BeOne Medicines Ltd
ONC
|
+$774M |
| 3 |
Illumina
ILMN
|
+$691M |
| 4 |
DexCom
DXCM
|
+$438M |
| 5 |
Netflix
NFLX
|
+$360M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$3.79B |
| 2 |
Amazon
AMZN
|
+$1.28B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$587M |
| 4 |
Zillow
Z
|
+$400M |
| 5 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
+$264M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 37.71% |
| 2 | Technology | 16.18% |
| 3 | Healthcare | 15.43% |
| 4 | Communication Services | 14.41% |
| 5 | Financials | 5.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
British American Tobacco
BTI
$128B
| $8.22M | ﹤0.01% |
219,238
+1,077
| +0.5% | +$38.6K |
|
227
Ascendis Pharma A/S
ASND
$16.8B
| $7.87M | ﹤0.01% |
+47,155
| New | +$7.8M |
|
228
Fortive
FTV
$18.6B
| $7.74M | ﹤0.01% |
144,934
-86,004
| -37% | -$4.42M |
|
229
Ionis Pharmaceuticals
IONS
$9.4B
| $7.14M | ﹤0.01% |
126,218
-4,794,625
| -97% | -$239M |
|
|
SINA
230
DELISTED
Sina Corp
SINA
| $5.58M | ﹤0.01% |
131,550
| – | – |
|
231
Health Catalyst
HCAT
$128M
| $5.31M | ﹤0.01% |
122,053
+59,738
| +96% | +$2.2M |
|
|
BRW
232
Saba Capital Income & Opportunities Fund
BRW
$339M
| $4.96M | ﹤0.01% |
+555,105
| New | +$4.89M |
|
233
American Well
AMWL
$230M
| $4.73M | ﹤0.01% |
9,335
+4,550
| +95% | +$2.63M |
|
|
MRC
234
DELISTED
MRC Global
MRC
| $4.31M | ﹤0.01% |
650,000
| – | – |
|
|
KLDO
235
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $4M | ﹤0.01% |
440,000
| – | – |
|
236
Veeva Systems
VEEV
$37.4B
| $3.82M | ﹤0.01% |
+14,024
| New | +$3.93M |
|
|
VEDL
237
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
| $3.79M | ﹤0.01% |
+431,984
| New | +$2.82M |
|
238
Relay Therapeutics
RLAY
$4.33B
| $3.32M | ﹤0.01% |
79,932
-5,584,989
| -99% | -$252M |
|
|
SOHU
239
Sohu.com
SOHU
$357M
| $3.19M | ﹤0.01% |
200,140
| – | – |
|
|
SAGE
240
DELISTED
Sage Therapeutics
SAGE
| $2.85M | ﹤0.01% |
32,916
+15,886
| +93% | +$1.17M |
|
241
Adicet Bio
ACET
$74.7M
| $2.55M | ﹤0.01% |
11,352
| – | – |
|
242
Korea Electric Power
KEP
$16B
| $1.96M | ﹤0.01% |
159,440
+5,460
| +4% | +$54K |
|
|
NSL
243
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $1.95M | ﹤0.01% |
375,012
| – | – |
|
244
Alector
ALEC
$199M
| $1.85M | ﹤0.01% |
122,406
+58,548
| +92% | +$728K |
|
245
Summit Therapeutics
SMMT
$11.1B
| $1.75M | ﹤0.01% |
372,261
| – | – |
|
|
UXIN
246
Uxin Ltd
UXIN
$282M
| $1.55M | ﹤0.01% |
17,761
| – | – |
|
247
Vontier
VNT
$4.74B
| $1.53M | ﹤0.01% |
+45,779
| New | +$1.41M |
|
248
WEC Energy
WEC
$35.1B
| $1.22M | ﹤0.01% |
13,262
| – | – |
|
|
BLUE
249
DELISTED
bluebird bio
BLUE
| $1.01M | ﹤0.01% |
1,801
-52,785
| -97% | -$33.5M |
|
250
NextEra Energy
NEE
$177B
| $930K | ﹤0.01% |
12,056
| – | – |
|
Similar funds
Baillie Gifford & Co's Q4 2020 Portfolio in Review
As of Q4 2020, Baillie Gifford & Co held 443 positions worth $180B, up 24% from $145B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Baillie Gifford & Co's Q4 2020 filing shows 192 new, 135 increased, 77 reduced and 14 closed positions. Its largest new stake was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M. The largest sale was Tesla, an estimated $3.79B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, up from 37% a quarter earlier, followed by Technology and Healthcare.
- Baillie Gifford & Co's largest Q4 2020 buy was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M.
- Baillie Gifford & Co added most to Moderna in Q4 2020, an estimated $1.73B increase.
- Baillie Gifford & Co's biggest Q4 2020 reduction was Tesla, cutting an estimated $3.79B.
- Baillie Gifford & Co fully exited TD Ameritrade Holding Corp in Q4 2020, selling an estimated $264M.
- Baillie Gifford & Co's ten largest holdings make up 43% of its $180B portfolio in Q4 2020.
- Baillie Gifford & Co opened 192 new positions and closed 14 in Q4 2020.
- Baillie Gifford & Co's portfolio value rose 24% quarter-over-quarter to $180B.
Based on Baillie Gifford & Co's 13F filing for Q4 2020, filed 10 Feb 2021.